Trial Profile
A multicenter, randomized, double-blind, placebo-controlled, 4-arm, 26 week parallel-group study to evaluate the safety, tolerability and anti-inflammatory effect of three oromucosal doses of Sativex® in patients with mild cognitive impairment of Alzheimer type or early Alzheimer dementia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Mar 2018
Price :
$35
*
At a glance
- Drugs Nabiximols (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Therapeutic Use
- 02 Mar 2018 Status changed from recruiting to discontinued.
- 24 May 2017 New trial record